<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Myeloid <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (MS) is a localized, extramedullary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) that typically presents either de novo or concomitantly with myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients who have MS must be treated with intensive chemotherapy, as are patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, because MS usually progresses to a systemic manifestation and leads to dismal outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>FIP1L1-PDGFRA-associated MPN, a subtype of myeloid and lymphoid <z:hpo ids='HP_0002664'>neoplasm</z:hpo>, is characterized by <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and abnormalities in the PDGFRA, PDGFRB or FGFR1 gene </plain></SENT>
<SENT sid="3" pm="."><plain>Fusion of the FIP1L1 and PDGFRA genes activates the tyrosine kinase </plain></SENT>
<SENT sid="4" pm="."><plain>As a result, <z:chebi fb="0" ids="31690">imatinib mesylate</z:chebi> (IM) is widely used for the treatment of this disorder </plain></SENT>
<SENT sid="5" pm="."><plain>The coexistence of FIP1L1-PDGFRA-associated MPN and MS is extremely rare </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with this condition fail to achieve durable remission and long-term survival without a combination of intensive chemotherapy and IM </plain></SENT>
<SENT sid="7" pm="."><plain>Here, we report a case of MS and FIP1L1-PDGFRA-associated MPN that was successfully treated with IM monotherapy </plain></SENT>
</text></document>